The risk that Kentgrove would be used to fund recurrent expenditure weighed heavily on the SP. If however MSB can demonstrate how they will use it directly to commercialise infant aGVHD in the US, I don't see it being as big of a concern to investors.
MSB trading, page-166
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 98.5¢ | 91.5¢ | $4.743M | 4.999M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123302 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |